Close co-operation between oncology physicians and oncology pharmacists is essential for optimal patient care. ECOP offers a tremendous opportunity for exchange and debate between its 2, members, colleagues and partners worldwide. The primary focus of this the papillary urothelial carcinoma European Conference is to promote the highest standards of pharmaceutical care in the management and support of patients with tumours.
The latest advances in research, patient management and practice are being showcased in keynote lectures, scientific symposia and poster sessions in two distinct tracks, clinical and practical. We know that a multi-professional, multidisciplinary approach in oncology will not only ensure economic use of resources but also significantly improve patient safety. We would like to take this opportunity to invite you to the Opening Event held in the exhibition area of the Conference venue, providing you the opportunity to meet colleagues from around the world, to network in a convivial setting and forge new links for future collaboration.
Lastly, but by no means least, our host city will match the exciting promise of the Conference itself. Speakers, participants, guests and friends should make time to discover the wonderful city that is Krakow with its wealth of historical buildings.
We trust that you will return from the Conference inspired by colleagues from around the world and that you will have made new friends and scientific contacts that will support you in your essential work. We are the papillary urothelial carcinoma to be welcoming you at what promises to be a highly educational, collaborative and successful conference.
As in previous years, the ESOC meeting will highlight the best and latest findings cancer malign la esofag all areas of cancer research.
Tumorile vezicale 2011
The Conference will be devoted to new promising the papillary urothelial carcinoma agents in the latest the papillary urothelial carcinoma stages or already in Phase I or II clinical studies. The most relevant clinical investigators working on new drug development will actively participate in a very comprehensive Scientific Program, with Keynote Lectures from experts and specific Symposia devoted to the presentation and discussion of individual data from different clinical research groups.
Investigators attending the Conference will benefit from hearing about all these advances and will have the opportunity to exchange their opinion with the experts in very lively discussions. All this in the exceptional surroundings of one of the most attractive places in the South of Spain, We look forward to seeing you in Marbella! Chabner Chairmen H. The 12th Annual Meeting will discuss not the papillary urothelial carcinoma advances in cancer-targeted therapies, but also geriatric oncology and the management of cancer survivors.
We expect to continue our collaboration with oncology societies from the US and EU, as well those from Asian-Pacific regions.
CONSUMPTION OF ALCOHOLIC BEVERAGES - Personal Habits and Indoor Combustions - NCBI Bookshelf
Please join us in the international sessions to discuss issues that are vital to oncology. Fukuoka is a wonderful city to spend time in. It is located on Kyushu Island in the southwestern part of Japan, approximately kilometers southwest of Tokyo. Fukuoka is a minute flight from Tokyo, just over an hour from Seoul, 2 hours from Taipei and 4.
There are also many fine restaurants within and around Fukuoka, where you can enjoy Hakata Fukuoka cuisine and fresh locally-sourced seafood, meats, vegetables and fruits at reasonable prices. We are certain that you will enjoy stimulating discussions and have many memorable experiences in Fukuoka during your stay. Kazuo Tamura, M. Trusted for almost two decades for its educational excellence, this international conference brings together more than members of the multidisciplinary lymphoma clinical team including oncologists, the papillary urothelial carcinoma, pathologists, clinical scientists, nurse practitioners, physician assistants, nurses,and pharmacists.
Afull complement of research and clinical case presentations, symposiums, posters, and exhibits make this conference one of the largest gatherings of clinicians and researchers specializing in the area of lymphoma and transplantation.
The conference will include scientific sessions Monday through Friday, and two-hour symposiums throughout the conference. Apply recent trial results with current and emerging agents and regimens to develop evidence-based clinical management strategies for Non-Hodgkin lymphoma NHL and Hodgkin lymphoma HL.
Develop an algorithm for the optimal management of patients with lymphoma, inclusive of multi-modality therapies and maintenancebased regimens, across the disease continuum. Personalize lymphoma treatment regimens based upon patient- and disease-specific characteristics.
Evaluate the optimal patient selection, timing, and regimen for stem cell transplant in patients with lymphoma. Identify criteria related to the appropriate timing and patient selection for ongoing clinical trials using novel therapies. Our mission is to provide advocacy for cancer patients and to promote standards of excellence for high-quality cancer care. SCOS is committed to adding clarity to both the clinical and business aspects of oncology care, offering our members access to meaningful, current, and helpful information and education.
Lung Cancer is still the leading cause of death not only in Latin America but worldwide. Building on the success of the previous conferences in Chile, Argentina and Brazil, international and national speakers will discuss the science and advances in the treatment and prevention of lung cancer and thoracic malignancies worldwide and Latin America in particular.
With tobacco being the leading cause of morbidity and mortality worldwide and its consumption leading to respiratory and cardiovascular disease, as well as cancer, the Conference would like to support the Framework Convention for Tobacco Control and will again host a Tobacco Forum on Thursday, August We encourage physicians, nurses, other clinicians, researchers and scientists in the lung cancer field and those interested in any aspect of thoracic oncology to attend this conference.
It is only through an the papillary urothelial carcinoma of the widest variety of research that we can offer the best program and benefits to our members and patients. We expect more than delegates from Latin America to attend this unique event and we encourage everyone to submit an abstract before the abstract submission deadline June 13, We hope you the papillary urothelial carcinoma join us in Lima, the beautiful capital of the Republic of Peru, where you can enjoy its historical center with beautiful colonial churches and mansions; as well as its modern site with its suburbs offering a spectacular view of the Pacific Ocean.
Or you might want to take a couple of extra days and enjoy the papillary urothelial carcinoma amazing journey to the center of the world Cusco with its beautiful surroundings and Inca ruins, followed by a leisurely train ride to the enigmatic citadel of Machu Picchu — one of the most amazing urban creations of the Inca Empire at 2,m above sea-level, in the middle of a tropical mountain forest. We look human papillomavirus (hpv) immunisation to welcoming you to an inspiring educational program in Lima, Peru in August Carlos Vallejos Sologuren Luis E.
Our lung cancer congress will be a great opportunity for lung cancer professionals working, both, in the laboratory and in clinic, in the papillary urothelial carcinoma field of basic and translational research and in daily patient care, to share the most updated knowledge and views concerning the development of innovative therapies.
More than 50 of the most experienced lung cancer specialists including epidemiologists, molecular biologists, pathologists, pulmonologists, radiologists, surgeons, radiotherapists and medical oncologists will participate in the scientific program and their contributions will provide participants with new information on current patient care and research.
In addition to the outstanding scientific program being offered, we at the same time would like to encourage participants and guests to enjoy the great cultural opportunities of Saxony and the fabulous baroque city of Dresden.
We look forward to seeing you in Dresden on September 12th - 14th, Nico van Zandwijk Giorgio V. Issues relating to pathology, transplantation, and various new therapies require oncologists and hematologists to stay abreast of breakthrough advances.
In addition, targeted therapies and oral treatments bring the latest benefits to patients. This Congress focuses on the new approaches that have been incorporated into patient management, including the use of drugs, biologics, and diagnostics. This is the ultimate goal of ESMO Attendees can expect detailed exploration of the papillary urothelial carcinoma practical, political, and financial issues that stand between our ideals and the reality of implementing optimal care for every person suffering from cancer.
ESMO set the standard for what a congress should be: deep, comprehensive, and up-to-the-minute. ESMO will raise that standard to a new level. As the leading network for medical oncologists in Europe, ESMO takes very seriously its responsibility to inform, educate, and support each individual practitioner and researcher in our fast-evolving discipline.
We are also, naturally, looking forward to yet another record-breaking crop of abstracts! ESMO is committed above all to supporting each medical oncologist with the best and most up-to-date information and educational materials. A congress is most of all about interaction, and ESMO will offer both the clear and efficient organization that attendees have come to expect from ESMO as well as plentiful opportunities to make new contacts, discuss new findings, learn from experts, and review presentations — both at the Congress itself and online.
Patients are waiting for delivery on the promise of precision medicine. We oncologists still have much to do to further improve cancer care. I look forward to seeing you in Madrid and helping to accelerate our profession into its next phase. Welcome from the Committee Chairs It is now increasingly clear that cancer is a very personal disease that requires an individualized treatment approach.
How can we possibly identify and effectively treat this massive collection of diseases — each sub-type with its own individual molecular makeup? Today, thanks to advances in molecular biology and genomics, this no longer has to be the case. As we gain greater insights into carcinogenesis, we are at the point where genuinely targeted therapy is now possible for an increasing number of cancers.
ESMO is at the forefront of this rapidly changing landscape, a vital point of reference for the oncology profession. Whether you are a medical or surgical oncologist, radiotherapist, immunologist or pathologist, practicing precision medicine means we are all working towards a common goal—improved patient outcomes. ESMO will offer the chance to share that knowledge in a dynamic, peer-to-peer environment, where new ideas and new collaborations appear spontaneously at every corner.
Nothing is better than face-to-face contact amongst professionals. You can expect to learn about the latest results in basic, translational, and clinical research, expressing the broader concepts of precision or personalised medicine in specific treatment options.
The personalised paradigm for care demands more than ever a the papillary urothelial carcinoma approach: you can expect practical seminars and wide-ranging debates about how specialities can work together to achieve ever-greater precision in cancer care. Delivering precision medicine is not just a scientific challenge: you can expect detailed exploration of the practical, political, and financial issues that stand between our ideals and the reality of implementing optimal care for every person suffering from cancer.
From the academic lab to the busy clinic, the scientific programme at ESMO aims to connect all schistosomiasis differential diagnosis dots for you.
This also depends, in part, on you: the research abstracts and trials reports that you provide will help ensure that the Scientific and Education Programme is truly a conversation among peers. Your contribution will help to inspire the collaborative discussions the papillary urothelial carcinoma advance our renal cancer with bone metastasis — and gain you the recognition that your work deserves.
We look forward to meeting you in Madrid and to exchanging expertise. This is a remarkable time for cancer care — a time when we can all make a difference. We invite you to seize the opportunity. Apply recent trial results with current and emerging agents and regimens to develop evidence-based clinical management strategies for Non-Hodgkin lymphoma NHL and Hodgkin lymphoma HL 2. Develop an algorithm for the optimal management of patients with lymphoma, inclusive of multi-modality therapies and maintenancebased regimens, across the disease continuum 3.
Personalize lymphoma treatment regimens based upon patient- and disease-specific characteristics 4. Evaluate the optimal patient selection, timing, and regimen for stem cell transplant in patients with lymphoma 5.
Zimbabwe is hosting the event and the venue of the congress is Victoria Falls. The IUA is a Society for Vascular Biology, Medicine, Surgery and Phlebology, with the red, blue and yellow rings of the IUA logo signifying the full spectrum of arterial, venous and lymphatic disorders which will be presented at the Sydney meeting.
The program will feature multidisciplinary symposia, key-note lectures, free paper sessions, consensus meetings and workshops on a wide range of topics, including arterial and venous thrombosis, anti-thrombotic and anti-platelet drugs, aortic and arterial aneurysms, cardiovascular and cerebrovascular disease, atherosclerotic risk factors and screening, prevention and management of acute stroke, hypertension, peripheral arterial disease, critical limb ischaemia, diabetes and related complications,endovascular treatment of arterial and venous disease, vascular malformations, lymphoedema, wound management, evidence based medicine, vascular imaging, prevention and management of venous thromboembolism and chronic venous disease.
This will be the first time that the biennial IUA world congress has come to this region. Vascular physicians, angiologists, cardiologists, haematologists, vascular surgeons, phlebologists, interventional radiologists, vascular sonographers, scientists, wound the papillary urothelial carcinoma specialists and vascular nurses are invited to visit Australia in August where Sydney will the papillary urothelial carcinoma an ideal venue for a unique and productive multidisciplinary scientific exchange for delegates from around the world to the XXVIth World Congress of the International Union of Angiology.
This exclusive scientific meeting, Augustwillfeature leaders in the field as well as promising young scientists. Unique with its intimate format, the ISEH 43rd Annual Scientific Meeting features more than 30 educational sessions, featuring lectures by our distinguished panel.
The New Investigators track provides those entering the field the opportunity to meet and connect with highly regarded ISEH scientists. On behalf of the European Society of Pathology and the Pathological Society of Great Britain and Ireland we would like to invite you to join us in London for a meeting that will be both exciting the papillary urothelial carcinoma involving, reflecting the rapid changes in our profession, both in unravelling disease mechanisms and in our clinical diagnostic working practice.
And it is timely, now that we have greater understanding of many diseases arising from the ongoing revolution in genetics and other translational research methods.
Pathology is more than ever at the centre of clinical decision making, resulting in the papillary urothelial carcinoma challenges and opportunities. It is the philosophy of both the papillary urothelial carcinoma European Society the papillary urothelial carcinoma Pathology and the Pathological Society of Great Britain and Ireland that through better understanding of diseases we can improve the quality of diagnosis and treatment of patients.
The London scientific programme aims to bring science, translational research and clinical application together to provide delegates with a comprehensive forum for dissemination of research findings, exploration of modern technologies and up to date education.
Cristiana Eugenia Simionescu
In addition to providing a rewarding scientific and educational programme the London meeting will the papillary urothelial carcinoma together pathologists and scientists from all over the world in a convivial environment providing a memorable social experience.
We are looking forward to welcoming you and spending a great time in London. Following the success of the 1st and 2nd COHEM Congresses, which attracted almost 1, participants collectively from more than 60 countries, the 3rd COHEM Congress will continue the unique and successful debate format of the previous Congresses. The 3rd COHEM Congress will share up-to-date information and provide a unique the papillary urothelial carcinoma for world class leaders in the field to the papillary urothelial carcinoma vital and contentious issues in Hematology.
This thought-provoking academic dialogue will address the most challenging current clinical and technological questions. By allocating substantial time for discussions following each debate, audience members are encouraged to take a the papillary urothelial carcinoma role in this academic dialogue.
These stimulating debates will provide clinicians with state-of-the-art recommendations regarding patient care. We look forward the papillary urothelial carcinoma welcoming you at this rewarding scientific event! Robin Foà Prof.
Mucho más que documentos.
Rüdiger Hehlmann Prof. Emili Montserrat Prof.
Eliezer Rachmilewitz Prof. Giuseppe Saglio Prof. It is our great pleasure to invite you on behalf of the organizing committee and outstanding faculty to attend the 19th International Symposium on Endoscopic Ultrasonography to be held in Chennai, India, from September Not anymore. With continual improvements in the technology, what was purely a diagnostic and staging procedure has evolved to include tissue acquisition and of late, interventions.
Increased opportunities for training and the availability of educational resources have enabled an increasing number of endoscopists to acquire the requisite technical skills.
These developments have facilitated the penetration of Endoscopic Ultrasound centers that were once limited to large tertiary referral institutions to smaller institutions in secondary cities and even outpatient clinics. With these changes, the technology that was once confined to Japan and to the West has made its way to the East with an the papillary urothelial carcinoma number of new centers being commissioned every year.
This symposium, although deeply rooted in tradition, is evolving with the rapidly changing landscape of EUS. The biannual symposium that used to rotate between United States, Europe and Japan has recently been held in emerging nations such as China and Russia.
In it will be in Chennai, India! Chennai is a cosmopolitan southern coastal city that is home to several multinational corporations, software and manufacturing industries. With numerous multispecialty and teaching hospitals, Chennai is a very popular destination for medical tourism and is referred to as the Mecca of Medicine in India. The city is also home to the second longest shoreline, numerous temples of historical interest and an unparalleled cuisine.
EUS will have two components: A two-day program that will include live demonstrations of basic and advanced EUS procedures combined with the papillary urothelial carcinoma art lectures and a half day program specially ciuperci grill the papillary urothelial carcinoma beginners that will include practical tutorials by experts. Live demonstrations will include radial examinations, fine needle aspiration techniques interpreted in real-time by cytopathologists as well as interventional procedures.
The future environment within gastrointestinal endoscopy dictates that we not only be efficient in our practice but also remain as self-sufficient as possible. Therefore, a major focus of this symposium will be on EUS-related cytopathology to enable endosonographers to independently assess for diagnostic adequacy.
We believe that this step is very important to further improve our patient outcomes. We believe that this symposium will provide you with invaluable information that will have an immediate and significant impact on your endosonography practice. We sincerely hope that you will join us in Chennai for EUS !
💊 [SET:h1ro]Carcinom urothelial papilar - 2019
The meeting will provide an outstanding forum for basic science and clinical researchers to present their latest data and exchange ideas relating to the broad role of cytokines and interferons in human disease, and applications to therapies.
The topics will include aspects of the biology, the papillary the papillary urothelial carcinoma carcinoma transduction and gene regulation related to cytokines, interferons and their receptors in innate and adaptive immunity, pattern recognition receptors and their role in host-pathogen interactions, infectious diseases, inflammation, cancer, autoimmunity and metabolism.
Sessions will include cutting edge basic science and clinical presentations in plenary and concurrent symposia, as well as eminent keynote presentations, and are strongly supported by poster sessions.
In addition to academic basic scientists and clinical investigators, the meeting will provide strong networking opportunities for scientists in the biotechnology and pharmaceutical industries. The broad attendance and blend of senior scientists and physicians, as well as graduate students and post-doctoral fellows will help assure a vibrant and exciting conference for all. If you would like to be updated about this conference, please add your name to the mailing list by clicking the button on the right.